Technical Analysis for RGEN - Repligen Corporation

Grade Last Price % Change Price Change
grade D 79.74 0.92% 0.73
RGEN closed up 0.92 percent on Friday, September 13, 2019, on 81 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Down
See historical RGEN trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Multiple of Ten Bearish Other 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New Downtrend Bearish 0.92%
Calm After Storm Range Contraction 0.92%
Lower Bollinger Band Walk Weakness 0.92%
Multiple of Ten Bearish Other 0.92%
Below Lower BB Weakness 0.92%

Older signals for RGEN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Repligen Corporation, a life sciences company, engages in the development, production, and commercialization of consumable products used in the process of manufacturing biological drugs. Its bioprocessing products are sold to various life sciences and biopharmaceutical companies worldwide. The company manufactures Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. It also supplies various growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, the company develops and markets its OPUS brand series of pre-packed ‘plug-and-play' chromatography columns, and provides ELISA test kits to ensure final product quality. Further, Repligen has a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and a orphan drug candidate in Phase 1 development. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Biotechnology Biopharmaceutical Life Sciences Natural Sciences Consumable Products Monoclonal Antibody Bioprocessing
Is RGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 99.25
52 Week Low 48.26
Average Volume 616,082
200-Day Moving Average 69.2575
50-Day Moving Average 89.3098
20-Day Moving Average 89.417
10-Day Moving Average 86.342
Average True Range 3.6144
ADX 26.4
+DI 13.7287
-DI 32.2203
Chandelier Exit (Long, 3 ATRs ) 84.5768
Chandelier Exit (Short, 3 ATRs ) 88.6232
Upper Bollinger Band 100.1673
Lower Bollinger Band 78.6667
Percent B (%b) 0.05
BandWidth 24.045316
MACD Line -2.427
MACD Signal Line -0.7284
MACD Histogram -1.6986
Fundamentals Value
Market Cap 2.97 Billion
Num Shares 37.3 Million
EPS 0.51
Price-to-Earnings (P/E) Ratio 156.35
Price-to-Sales 12.40
Price-to-Book 6.72
PEG Ratio 2.55
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 84.18
Resistance 3 (R3) 84.10 82.53 83.44
Resistance 2 (R2) 82.53 81.40 82.58 83.19
Resistance 1 (R1) 81.14 80.70 81.84 81.22 82.95
Pivot Point 79.57 79.57 79.92 79.62 79.57
Support 1 (S1) 78.18 78.44 78.88 78.26 76.53
Support 2 (S2) 76.61 77.74 76.66 76.29
Support 3 (S3) 75.22 76.61 76.04
Support 4 (S4) 75.30